Search details
1.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
J Clin Oncol
; 42(13): 1499-1508, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38277619
2.
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Blood Adv
; 8(4): 909-915, 2024 Feb 27.
Article
in English
| MEDLINE | ID: mdl-38207208
3.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol
; 16(1): 73, 2023 07 08.
Article
in English
| MEDLINE | ID: mdl-37422688
Results
1 -
3
de 3
1
Next >
>>